Prophylaxis of HCV reinfection and direct‐acting antiviral agents during liver transplantation

By  

LIVER TRANSPLANTATION, Vol. 1527-6465, Iss. 10, 2015-10 ,pp. : 1327-1329

John Wiley & Sons Inc

Access to resources Recommend Favorite

P151: Improvement of virologic response and liver elasticity in HCV‐patients after liver transplantation through treatment with the new direct‐acting antivirals

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 94-95

John Wiley & Sons Inc

Access to resources Recommend Favorite

Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct‐acting antiviral treatment for HCV

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. 1, 2018-01 ,pp. : 76-83

John Wiley & Sons Inc

Access to resources Recommend Favorite

Will IL28B polymorphism remain relevant in the era of direct‐acting antiviral agents for hepatitis C virus?

By  

HEPATOLOGY, Vol. 56, Iss. 1, 2012-07 ,pp. : 373-381

John Wiley & Sons Inc

Access to resources Recommend Favorite

The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1365-1372

John Wiley & Sons Inc

Access to resources Recommend Favorite